financetom
Business
financetom
/
Business
/
Progressive EPS Decline Likely in 2026, 2027, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Progressive EPS Decline Likely in 2026, 2027, Morgan Stanley Says
Oct 20, 2025 6:30 AM

09:14 AM EDT, 10/20/2025 (MT Newswires) -- Progressive's (PGR) September results have likely eroded the optimistic outlook for its stock, Morgan Stanley said in a Monday note.

The excess profit charge from Florida is likely a one-time event, and the company's profit expectations for 2026 and 2027 will be challenged by slower rate pricing growth and potentially higher loss cost trends, Morgan Stanley analysts said.

Inflationary pressures and competitive market conditions suggest that market margins will likely erode and growth likely to decelerate into 2026, resulting in EPS compression in 2026, if not also 2027, they said.

Progressive's marketing efficiency, measured by the number of gained policies in force versus marketing dollars spent, is expected to drop further with increased competition, signaling slower growth ahead, the analysts said.

The outlook for 2026 indicates that marketing efficiency will approach zero, with marketing spending critical to maintaining the current level of market share for the year, according to the note.

The analysts said that two key metrics for the company appear to be "difficult" in 2026: reaccelerating growth, due to increased competition and the overcapacity of the industry; and consistent combined ration improvements, due to potentially higher inflation and the need to reduce pricing to maintain market share.

Morgan Stanley downgraded the company's stock to underweight from equal-weight, and the price target was reduced to $214 from $265.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Form 8.3
Form 8.3
Mar 23, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:   Sand Grove Capital Management LLP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming...
Market Chatter: Takeda, Eli Lilly to Face Class Action Over Actos Cancer Risk
Market Chatter: Takeda, Eli Lilly to Face Class Action Over Actos Cancer Risk
Mar 23, 2026
10:58 AM EDT, 03/23/2026 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) and Eli Lilly ( LLY ) will face a multibillion-dollar class action accusing them of concealing diabetes drug Actos' bladder cancer risk after the US Supreme Court rejected their appeal, Bloomberg reported Monday, citing a court order. The high court rejected the companies' argument that the lawsuit should...
Form 8.3
Form 8.3
Mar 23, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Form 8.3
Form 8.3
Mar 23, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:   Sand Grove Capital Management LLP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming...
Copyright 2023-2026 - www.financetom.com All Rights Reserved